Fibroblast Activation: A Novel Mechanism of Heart Failure in Light Chain Cardiac Amyloidosis?
- PMID: 36357139
- DOI: 10.1016/j.jcmg.2022.08.019
Fibroblast Activation: A Novel Mechanism of Heart Failure in Light Chain Cardiac Amyloidosis?
Keywords: FAPI; cardiac amyloidosis; fibroblast activation; light chain amyloidosis; positron emission tomography/computed tomography.
Conflict of interest statement
Funding Support and Author Disclosures Dr Dorbala has received research support from National Institutes of Health/NHLBI, R01 HL130563, R01 HL150342, R01 HL159987, K24 HL157648, and AHA 16CSA28880004 and AHA 19SRG34950011; consulting fees from Pfizer and GE Health Care; and investigator-initiated research grants from Pfizer, Attralus, and Phillips.
Comment on
-
Feasibility of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Light-Chain Cardiac Amyloidosis.JACC Cardiovasc Imaging. 2022 Nov;15(11):1960-1970. doi: 10.1016/j.jcmg.2022.06.004. Epub 2022 Sep 14. JACC Cardiovasc Imaging. 2022. PMID: 36357138
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
